As GLP-1 medications like Ozempic and Wegovy become more commonly used to treat obesity, new research is showing that having a certain gene might make it more likely for the drug to be successful.

The Cleveland Clinic published a study that shows variations of a gene known as Neurobeachin could dictate how much weight a person using a GLP-1 would lose.

The study found that those who had a "responsive" genetic score were 82% more likely to have significant weight loss. Those who had a non-responsive genetic score were nearly 50% more likely not to lose weight.

This study could help doctors better treat patients.

“With some additional work and future studies, we could take this score we developed with this gene and combine it with lifestyle factors and other personal factors, maybe other

See Full Page